

ORAL PRESENTATION

Open Access

# Comparing active treatments at phase II: using multiple criteria to find the optimal treatment to take forward to phase III

Michael Sweeting, Martin Law\*

From 2nd Clinical Trials Methodology Conference: Methodology Matters  
Edinburgh, UK. 18-19 November 2013

In a Phase II RCT with multiple active treatments, we may often wish to take forward a treatment to Phase III based on multiple criteria and outcomes. In addition to efficacy, factors such as cost and the adverse event rate may play a key role in the decision making process. Using a Bayesian analysis, all relevant criteria can be considered, and a utility function employed to obtain the optimal treatment.

An example is presented, detailing the results of an RCT comparing Moxifloxacin, Doxycycline and Azithromycin against placebo in the treatment of COPD, using the criteria efficacy (reduction in airway bacterial counts), adverse event profile, treatment adherence, resistance to study drug and cost.

The relevant criteria of importance were chosen by the trial investigators. For each chosen criterion, a Bayesian analysis was performed and the effect estimates ranked, with uncertainty in the effect sizes automatically propagated to uncertainty in the ranks.

Each criterion was assigned a weight a priori, and these weights determined the relative importance of each criterion. The weights were chosen based on an elicitation exercise conducted with the clinicians, whereby possible outcomes were presented under various weighting scenarios in an iterative exercise until a consensus was achieved.

Finally, a utility function combined the elicited weights with the criteria ranks to provide an overall ranking for each treatment. The treatment recommended for Phase III was taken to be the one with the highest mean utility.

Published: 29 November 2013

doi:10.1186/1745-6215-14-S1-O117

**Cite this article as:** Sweeting and Law: Comparing active treatments at phase II: using multiple criteria to find the optimal treatment to take forward to phase III. *Trials* 2013 **14**(Suppl 1):O117.

MRC Biostatistics Unit, Cambridge, UK



© 2013 Sweeting and Law; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

